Factive Should Be Used Second-Line For Treatment Of Acute Sinusitis – Cmte.
Executive Summary
Oscient's Factive would be a second-line treatment of acute bacterial sinusitis, FDA's Anti-Infective Drugs Advisory Committee said in recommending against approval of a supplemental claim for gemifloxacin in ABS Sept. 12.
You may also be interested in...
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)
Past FDA Action Is Not Necessarily Predictive Of Future Behavior – Temple
Sponsors should not assume clinical trials are immune from evaluation according to updated efficacy standards, even if parameters are initially agreed upon with the agency